Impacts of Cancer on Platelet Production, Activation and Education and Mechanisms of Cancer-Associated Thrombosis.
Léa PlantureuxDiane MègeLydie CrescenceFrançoise Dignat-GeorgeChristophe DuboisLaurence Panicot-DuboisPublished in: Cancers (2018)
Platelets are small anucleate cells that are traditionally described as the major effectors of hemostasis and thrombosis. However, increasing evidence indicates that platelets play several roles in the progression of malignancies and in cancer-associated thrombosis. A notable cross-communication exists between platelets and cancer cells. On one hand, cancer can "educate" platelets, influencing their RNA profiles, the numbers of circulating platelets and their activation states. On the other hand, tumor-educated platelets contain a plethora of active biomolecules, including platelet-specific and circulating ingested biomolecules, that are released upon platelet activation and participate in the progression of malignancy. The numerous mechanisms by which the primary tumor induces the production, activation and aggregation of platelets (also known as tumor cell induced platelet aggregation, or TCIPA) are directly related to the pro-thrombotic state of cancer patients. Moreover, the activation of platelets is critical for tumor growth and successful metastatic outbreak. The development or use of existing drugs targeting the activation of platelets, adhesive proteins responsible for cancer cell-platelet interactions and platelet agonists should be used to reduce cancer-associated thrombosis and tumor progression.
Keyphrases
- pulmonary embolism
- papillary thyroid
- small cell lung cancer
- red blood cell
- squamous cell carcinoma
- induced apoptosis
- single cell
- drug delivery
- squamous cell
- young adults
- oxidative stress
- quality improvement
- cell death
- cell proliferation
- endoplasmic reticulum stress
- anti inflammatory
- bone marrow
- high glucose
- childhood cancer
- nucleic acid